Dexchlorpheniramine

Mechanism-of-action classes: Histamine H1 Receptor Antagonists; Monoamine Oxidase Inhibitors.

• Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.ICD-10: H10.9, J30.9

• - Use in Newborn or Premature Infants This drug should not be used in newborn or premature infants. Use in Nursing Mothers Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.contraindicated

DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT. Recommended Dosage Adults and Children 12 years of age and older: 2 mg (1 teaspoonful) Children 6 to 11 years: 1 mg (1/2 teaspoonful) Children 2 to 5 years: 0.5 mg (1/4 teaspoonful) Doses are generally given every 4 to 6 hours.

Antihistamines should be used with considerable caution in patients with: Narrow angle glaucoma Stenosing peptic ulcer Pyloroduodenal obstruction Symptomatic prostatic hypertrophy Bladder neck obstruction Use in Children In infants and children, especially, antihistamines in overdosage may cause hallucinations, convulsions, or death. As in adults, antihistamines may diminish mental alertness in children. In the young child, particularly, they may produce excitation. Use in Pregnancy Experience with this drug in pregnant women is inadequate to determine whether there exists a potential for harm to the developing fetus. Use with CNS Depressants CORPHENA Oral Solution has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.). Use in Activities Requiring Mental Alertness Patients should be warned about engaging in activities requiring mental alertness such as driving a car or operating appliances, machinery, etc. Use in the Elderly (approximately 60 years or older) Antihistamines are more likely to cause dizziness, sedation, and hypotension in elderly patients.

General: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and the throat. Cardiovascular System: Hemolytic anemia, thrombocytopenia, agranulocytosis. Hematologic System: Hemolytic anemia, thrombocytopenia, agranulocytosis. Nervous System: Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesias, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions. G.I. System: Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation. G.U. System: Urinary frequency, difficult urination, urinary retention, early menses. Respiratory System: Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness. Call your doctor for medical advice about side effects. You may voluntarily report side effects to FDA at 1-800-FDA-1088. Questions or comments? Call BluCrest Pharmaceuticals, LLC at 1-844-700-5011.

Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in children. Atropine-like signs and symptoms—dry mouth, fixed, dilated pupils, flushing, and gastrointestinal symptoms may also occur. If vomiting has not occurred spontaneously the patient should be induced to vomit. This is best done by having the patient drink a glass of water or milk after which the patient should be made to gag. Precautions against aspiration must be taken, especially in infants and children. Saline cathartics , such as milk of magnesia, draw water into the bowel by osmosis and therefore, are valuable for their action in rapid dilution of bowel content. Stimulants should not be used. Vasopressors may be used to treat hypotension.

• Jul 16, 2018ANDAANDA202520Pharmobedient

1. 1Pyrexia757.5%
2. 2Infusion Related Reaction646.4%
3. 3Febrile Neutropenia626.2%
4. 4Rash515.1%
5. 5Off Label Use505.0%
6. 6Erythema494.9%
7. 7Dyspnoea474.7%
8. 8Nausea454.5%
9. 9Malaise414.1%
10. 10Neutropenia404.0%
11. 11Cytokine Release Syndrome383.8%
12. 12White Blood Cell Count Decreased373.7%
13. 13Hypersensitivity363.6%
14. 14Diarrhoea353.5%
15. 15Pruritus343.4%

The 10 most recently updated of 29 ClinicalTrials.gov registrations naming Dexchlorpheniramine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL).
  Not yet recruiting · Phase 2 · Interventional · 82 enrolled · French Innovative Leukemia Organisation
  NCT07624799updated 2026-06-03
• Hemodynamic Instability Prevented With Polaramine® Infusion Before Extracorporeal Circulation
  Completed · Phase 3 · Interventional · 18 enrolled · University Hospital, Bordeaux
  NCT02675374updated 2026-05-19
• Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis
  Completed · Phase 3 · Interventional · 8 enrolled · Assistance Publique - Hôpitaux de Paris
  NCT03920722updated 2026-05-06
• Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)
  Recruiting · Phase 2 · Interventional · 90 enrolled · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
  NCT06766825updated 2026-04-03
• Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis
  Recruiting · Phase 2 · Interventional · 33 enrolled · Assistance Publique - Hôpitaux de Paris
  NCT06940661updated 2026-03-06
• A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
  Terminated · Phase 3 · Interventional · 16 enrolled · Genzyme, a Sanofi Company
  NCT03368664updated 2025-11-26
• Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders
  Recruiting · Phase 3 · Interventional · 90 enrolled · Centre Hospitalier Universitaire de Saint Etienne
  NCT05136976updated 2025-11-24
• Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF
  Recruiting · Phase 3 · Interventional · 196 enrolled · Assistance Publique - Hôpitaux de Paris
  NCT04702256updated 2025-11-24
• Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab
  Completed · Phase 3 · Interventional · 97 enrolled · Assistance Publique - Hôpitaux de Paris
  NCT02433522updated 2025-11-20
• Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
  Recruiting · Phase 1 · Phase 2 · Interventional · 20 enrolled · Fundacio Clinic Barcelona
  NCT05451784updated 2023-11-24

Frequently asked questions

How does Dexchlorpheniramine work?

Mechanism-of-action classes: Histamine H1 Receptor Antagonists; Monoamine Oxidase Inhibitors.

What is Dexchlorpheniramine used for?

According to FDA labeling, Dexchlorpheniramine carries indications including: Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.

What class of drug is Dexchlorpheniramine?

Dexchlorpheniramine is classified as Substituted alkylamines, Histamine H1 Receptor Antagonists, Monoamine Oxidase Inhibitors, Decreased Histamine Activity.

What are the brand names for Dexchlorpheniramine?

Dexchlorpheniramine is marketed under brand names including Ryclora.

What are the contraindications for Dexchlorpheniramine?

Dexchlorpheniramine labeling lists contraindications including: - Use in Newborn or Premature Infants This drug should not be used in newborn or premature infants. Use in Nursing Mothers Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, antihistamine therapy is contraindicated in nursing mothers.. Always consult the full prescribing information and a clinician.